Question explored with the scientific record
does ivermectin assist in controlling cancer?
Ivermectin is not a cancer treatment. It is a decades-old antiparasitic drug that has shown some anti-tumor activity in petri dishes and in mice, and that is a very long way from helping a human patient.
The evidence you retrieved is almost entirely preclinical. One study in canine mammary tumor cells and mouse xenografts found that ivermectin slowed tumor growth by arresting the cell cycle and suppressing WNT/β-catenin signaling [1]. That is a mechanism worth studying. But the same study showed apoptosis only at high concentrations and long exposures, and the mouse dose was 0.1 mg per mouse, which is not a human dose [1]. No human cancer patient received the drug in any trial you retrieved.
Here is the honest gap: there is no randomized controlled trial in humans, no cohort study, no case series with meaningful follow-up, and no long-term safety data for ivermectin as an anticancer agent. The in vitro concentrations that worked, 8 to 12 μM, are far above what is safely achievable in human blood with approved dosing. At those levels you are not treating cancer; you are poisoning the patient.
The burden of proof sits with anyone claiming ivermectin controls cancer in people. That burden has not been met. The preclinical signal is real but preliminary, and the history of cancer drugs is littered with compounds that shrank mouse tumors and did nothing in humans.
Confidence: high that ivermectin is not an established cancer treatment, and high that the evidence for its use in humans is essentially absent. If you are considering this for yourself or a family member, the honest answer is that no credible human data supports it, and the doses that showed effect in the lab are not safe to take.
Sources used 1
-
Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling
The study shows that repurposed anthelmintic ivermectin inhibits canine mammary tumor growth by causing G1 cell cycle arrest via downregulation of cyclin D1 and CDK4 and by suppressing WNT/β-catenin signaling, with efficacy observed in vitro in canine mammary tumor cell lines an…
DOI: 10.1186/s12917-019-2026-2